Abramson Cancer Center at Penn Medicine: Adenocarcinoma trials

The registry lists 11 Adenocarcinoma studies with Abramson Cancer Center at Penn Medicine as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 4Phase 2 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal TumorsTerminatedNCT03693846Phase 2Results posted
• Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based ChemotherapyCompletedNCT02303977Phase 2Results posted
• A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic AdenocarcinomaCompletedNCT01839799Phase 2Results posted
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerCompletedNCT01037790Phase 2Results posted
• Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract AdenocarcinomaCompletedNCT00948935Phase 2Results posted
• MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal AdenocarcinomaWithdrawnNCT04134468Phase 2
• A Study of Entinostat and FOLFOX in Subjects With Pancreatic AdenocarcinomaWithdrawnNCT03760614Phase 1
• A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic CancerCompletedNCT01506973Phase 1/2
• Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic CarcinomaCompletedNCT01456585Phase 1
• FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal CancerCompletedNCT01206530Phase 1/2
• Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal AdenocarcinomaTerminatedNCT00353457Phase 2